Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617

Puntos clave

• This research aims to explore the relationship between baseline inflammatory markers and clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving treatment with Lutetium-177–PSMA-617.
• Observational analysis of baseline inflammatory markers
• Assessment of clinical outcomes in treated patients
• Data collection from patient records
• Higher baseline inflammatory markers correlate with poorer clinical outcomes
• Inflammatory biomarkers may serve as useful prognostic indicators.